Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

57.16
-0.4700-0.82%
Post-market: 57.160.00000.00%19:30 EDT
Volume:2.23M
Turnover:127.83M
Market Cap:32.98B
PE:30.66
High:57.91
Open:57.64
Low:56.96
Close:57.63
52wk High:64.38
52wk Low:35.23
Shares:576.94M
Float Shares:392.53M
Volume Ratio:0.82
T/O Rate:0.57%
Dividend:0.91
Dividend Rate:1.59%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:4.83
PE(LYR):32.09

Loading ...

Royalty Pharma EVP Research & Investments Marshall Urist Sells 4,126 Shares for $238,812.88

Reuters
·
Oct 01

Royalty Pharma EVP Christopher Hite Disposes of 100,000 Common Shares Worth $5,853,719.88

Reuters
·
Sep 25

Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)

TIPRANKS
·
Sep 24

BRAIN Biotech Receives EUR 11.51 Million Milestone Payment from Royalty Pharma

Reuters
·
Sep 09

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Royalty Pharma Down Nearly 6%, on Pace for Largest Percent Decrease Since March 2025

Dow Jones
·
Sep 09

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09

Movement Alert|Royalty Pharma plc Falls 6.4% in Regular Trading, S&P 500 Index Inclusion Expectation Missed Triggering Selloff

Market Focus
·
Sep 09

Movement Alert|Royalty Pharma plc Falls 5.72% in Pre-Market Trading, S&P 500 Index Quarterly Rebalancing Inclusion Expectation Unmet

Market Focus
·
Sep 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 08

Royalty Pharma Announces Update on Novartis’ Phase 3 Topline Results for Pelacarsen

THOMSON REUTERS
·
Sep 05

Royalty Pharma - Expects to Recoup Investment and Earn Modest Return Despite Pelacarsen Failure

THOMSON REUTERS
·
Sep 05

Zenas BioPharma Highlights FDA Review Acceptance for Obexelimab IgG4-RD Filing in Corporate Presentation

Reuters
·
Aug 31

Royalty Pharma EVP and Chairman of Partnering Christopher Hite Sells 100,000 Shares for $6 Million

Reuters
·
Aug 20

Royalty Pharma CFO Terrance P. Coyne Sells USD 645,248 in Common Shares

Reuters
·
Aug 18

Royalty Pharma and Zealand Pharma Enter into Rusfertide Funding Agreement for $100 Million

THOMSON REUTERS
·
Aug 13

Zealand Pharma Sells Rusfertide Royalty Interests to Royalty Pharma for USD 100 Million

Reuters
·
Aug 13

Royalty Pharma Publishes Transcript of Q2 2026 Financial Results Call

Reuters
·
Aug 11

J.P. Morgan Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
Aug 11